Asthma  >>  velsecorat (AZD7594)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
velsecorat (AZD7594) / AstraZeneca
GRANIT, NCT03622112 / 2017-002483-40: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Completed
2b
808
Europe, Japan, US, RoW
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
AstraZeneca, Parexel
Asthma
09/19
09/19
NCT02479412 / 2014-005306-37: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Completed
2
54
Europe
800 μg AZD7594 once daily, High dose of AZD7594, 250 µg AZD7594 once daily, Medium dose of AZD7594, 58 µg AZD7594 once daily, Low dose of AZD7594, Placebo once daily, Placebo, Salbutamol, Rescue medication
AstraZeneca
Asthma, Efficacy, Safety
02/16
02/16

Download Options